Jiangsu Hengrui Medicine will develop, manufacture and license NOV03 and CyclASol in China, Hong Kong, Macau and Taiwan following the closing of an exclusive license agreement with Novaliq, according to a press release.
NOV03 (perfluorohexyloctane) is being developed as a treatment for dry eye disease associated with meibomian gland dysfunction, while CyclASol (cyclosporine A 0.1%) is an anti-inflammatory investigational drug for the treatment of moderate to severe dry eye disease.
“We believe that Jiangsu Hengrui Medicine, as a leading biopharmaceutical company in China, is the ideal
Uncategorized